Global financial crisis on China's import and export of traditional Chinese medicine has been fully reflected in the first quarter of statistical data: According to Customs statistics, in the first quarter, China's import and export volume of Chinese medicinal products to 4.3 billion U.S. dollars, up 8.7%, slower than 10.3 percentage points over the same period last year. Of these, 130 million U.S. dollars of imports, up 42.5%; exports 300 million U.S. dollars, down 1.5% - the first negative growth in exports over the years. The first quarter of 2009, each month, Chinese exports to volatile products, the chain down then up. February Chinese product exports, decreased by 23% to March, exports of Chinese medicine products chain greatly increased 40.6%. This shows that, as the country introduced a series of economic stimulus policies, a good signal to the export situation has begun to appear. Chinese crude drugs Exports fell significantly A quarter of China's total import and export volume of Chinese medicine and slices of 5.4 million tons, down 24.8%, import and export amounted to 130 million U.S. dollars, down 13.2%. Among them, the export volume of 4.4 million tons, down 24.9%; exports amounted to 100 million U.S. dollars, down 22.6%. Export volume and export value declined sharply, but the average prices rose slightly. Chinese crude drugs on the South Korean exports fell the most obvious decline in both number and value of 48% year on year. The main reason is China Chinese crude drugs Korea increased sulfur dioxide, heavy metals residue limits, to some extent, restricted the application of such products exported to Korea. However, a quarter of Chinese crude drugs in China in Taiwan and China's exports to Germany with good financial results, an increase of respectively 26.9% and 40.7%. Plant Extract Export amount ranks first in exports of Chinese medicine A quarter of the import and export volume of plant extract 1.3 million tons, up 24.7%, import and export amounted to 190 million U.S. dollars, up 41.5%. Among them, the export of 8,371 tons, down 5.07%; exports amounted to 140 million U.S. dollars, up 20.7%. Chinese plant extracts export accounted for 46.7% of the total exports, export growth of Chinese medicinal products is a major driving force. Plant extracts, the largest increase in export value is the natural pigment products. Bulk single product in the first quarter of stevia export value increased remarkably. Pure plant extracts with low exports and export prices are up slightly, these products are used for food additive industry. Plant extracts high purity price increase significantly over the previous year, but exports fell more, indicating the area of health care products for the plant extracts has decreased. Export markets, in the first quarter performance is the most prominent Indian market, 2008 came in the export market of plant extracts the eighth, the first quarter of this year rose to third place. The main products exported to India are natural pigments, spices and other crude plant extracts, widely used in food areas. A quarter of the two largest export market performance of Japan and the U.S. different. Increase exports to Japanese market, exports decline in the average export price fell by 22.7%; the U.S. market is in contrast to higher export growth, exports fell significantly, exports to the U.S. average price rose significantly, an increase of 111.5% . Since Japan imports of plant extracts in China except for health care products, the large part of Chinese herbs as raw materials. U.S. imports of plant extracts is mainly to use as food additives, low added value, the proportion of exports of such products to the United States gradually reduced. Chinese patent medicine Further increase the trade deficit The first quarter of this year, import and export amounted to 65.29 million U.S. dollars of proprietary Chinese medicines, down 11.6%, export prices declined by 20.7%. Among them, the exports 28,050,000 U.S. dollars, down 11.2%; imports amounted to 37.24 million U.S. dollars, down 11.9%. Trade deficit reached 9.19 million U.S. dollars. Asia is still the main export market of proprietary Chinese medicines, Chinese patent medicines accounted for 72.2% of global exports. Proprietary Chinese exports decline is the biggest Japanese market, exports fell by 11.7%; increase is the largest South Korean market, exports increased 580.8 percent year on year. South Korean exports to the extraordinary growth in March this year, mainly due to a trading company Anguo made two trade turnover reached 90 million, accounting for a quarter of a proprietary Chinese medicine in China exported to Korea 90% of the total. Such an increase of non-continuity, and do not represent significant growth in demand for the Korean market. Health Products Strong growth in exports In the first quarter, China's health products reached 46.66 million U.S. dollars, up 26.7%. Exports 22,820,000 U.S. dollars, up 29.5%; imports amounted to 23.84 million U.S. dollars, up by 24.2%. Trade deficit of 102 million. Health care products main export markets are Japan, the United States, Canada, France, Germany, quarter [FS: PAGE] are substantial growth year on year degree. As the United States and Europe has become a mature consumer market in health products and health products relatively cheap in China, so China's exports of health products in general less affected by the financial crisis. Outlook Chinese export situation will gradually getting better and better Although exports of traditional Chinese medicine there was a slight decline in the first quarter of this year, but the analysis of all major types of goods can predict the second quarter, the export situation of Chinese medicinal products will be gradually getting better. First, the Chinese crude drugs in the first quarter although the number and value of exports has declined, but there actually was an average price growth momentum. In addition, Chinese crude drugs ring in March rose by 49.4%, warming trends have been seen. In response to foreign technical trade barriers, China Medical Insurance Association has been active with the South Korean Pharmaceutical Association, input and output communication between agencies to ensure that trade facilitation; the same time they also begin to develop our exports of Chinese crude drugs industry standards to reduce technical trade barriers limit. Second, the plant extracts will remain the main driving force stimulating the export of Chinese medicine, plant extracts from the use of analysis, the overall demand for stability in the global market. Plant extracts the financial crisis prompted the change in market segmentation, India and Mexico as a new plant extracts market, huge demand for food additives in the field will greatly promote the export of plant extracts. Japan, U.S., EU and other developed countries and regional markets over the import of plant extracts used in Chinese herbs, or health care products in the field, the characteristics of its rigid requirements the financial crisis will not change greatly. Thirdly, the current Chinese patent medicines in the proportion of Chinese exports less exports declined slightly will not affect the overall export situation of Chinese medicine. The main export markets proprietary Chinese medicine in Asia, to seize the Asian markets, focusing on developing the Southeast Asian market, Quality brand, will make proprietary Chinese exports is beginning to pick. Fourth, health care products market is the most potential market. Export of data analysis, health care products before and after the financial crisis does not appear significant export market fluctuations, has been in a stable growth. In summary, the estimated annual import and export of Chinese products in general growth momentum will be maintained. I am an expert from China Chemicals Products, usually analyzes all kind of industries situation, such as baby coat hangers , jg hook.